1-<2-(trifluoromethyl)phenyl>urea | 13114-85-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-<2-(trifluoromethyl)phenyl>urea
• 英文别名: 1-(2-(trifluoromethyl)phenyl)urea；2-(trifluoromethyl)phenylurea；2-trifluoromethylphenylurea；1-[2-(Trifluoromethyl)phenyl]urea；[2-(trifluoromethyl)phenyl]urea
• CAS: 13114-85-7
• 化学式: C₈H₇F₃N₂O
• 分子量: 204.152
• InChiKey: PARAGKZGYKOQSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-<2-(trifluoromethyl)phenyl>urea 在 乙醇 、 sodium 、 溶剂黄146 作用下， 生成 1-(2-trifluoromethylphenyl)-5-((3-fluoro-4-(6-methoxy-7-(3-(4-morpholinyl)propoxy)quinolin-4-oxy)phenylamino)methylene)pyrimidine-2,4,6(1H,3H,5H)-trione
  参考文献：
  名称：

  Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors

  摘要：

  A series of novel quinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) in vitro. Most compounds showed moderate to excellent potency, with the most promising analogue 45 (c-Met half-maximal inhibitory concentration [IC50] = 1.15 nM) showing high selectivity versus 5 other tyrosine kinases, VEGFR-2, Flt-3, PDGFR-beta, c-Kit, and EGFR. Structure-activity relationship studies indicated that electron-donating groups on the phenyl ring at the 3-position of pyrimidine-2,4,6-trione were required to increase the electron density on the 5-(aminomethylene) pyrimidine-2,4,6-trione moiety. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.014
• 作为产物：
  描述：

  2-(三氟甲基)苯基硫脲 在 trans-3,5-dihydroperoxy-3,5-dimethyl-1,2-dioxolane 、 水 、 potassium hydroxide 作用下， 以 乙腈 为溶剂， 反应 0.17h， 以87%的产率得到1-<2-(trifluoromethyl)phenyl>urea
  参考文献：
  名称：

  Selective and facile oxidative desulfurization of thioureas and thiobarbituric acids with singlet molecular oxygen generated from trans-3,5-dihydroperoxy-3,5-dimethyl-1,2-dioxolane

  摘要：

  An efficient and facile procedure using trans-3,5-dihydroperoxy-3,5-dimethyl-1,2-dioxolane has been developed for oxidative desulfurization of thioureas and thiobarbituric acids. The reactions proceeded smoothly very fast under mild conditions in basic media at room temperature to afford the respective ureas in excellent yields. Simple procedure and work up, mild conditions, high yields, short reaction times, use of highly potent and non-toxic oxidant are the main merits of the present method.[GRAPHICS].

  DOI：

  10.1080/17415993.2015.1082181

文献信息

• [EN] DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ENRICHIS EN DEUTÉRIUM EN TANT QU'INHIBITEURS DE KINASES
  申请人：ASCEPION PHARMACEUTICALS INC

  公开号：WO2012028106A1

  公开（公告）日：2012-03-08

  The present invention provides deuterium-enriched heteroaryl-containing urea compounds (I) and use of the same for treating conditions mediated by protein kinase such as

  本发明提供了富含氘的杂环基脲化合物（I）以及利用这些化合物治疗由蛋白激酶介导的疾病的方法。
• Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors
  作者：Weike Liao、Gang Hu、Zhuang Guo、Deyu Sun、Lixia Zhang、Yanxin Bu、Yingxiu Li、Yajing Liu、Ping Gong

  DOI：10.1016/j.bmc.2015.06.026

  日期：2015.8

  A series of 4-(2-fluorophenoxy)quinoline derivatives containing an imidazolone moiety were designed, synthesized and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, H460, HT-29 and MKN-45). Most compounds showed moderate to excellent activities in enzyme and cellular assays. The most promising analog, 58 (c-Met IC50 = 1.42 nM), displayed 2.1-

  设计，合成并评估了一系列含咪唑酮部分的4-（2-氟苯氧基）喹啉衍生物对c-Met激酶和四种癌细胞系（A549，H460，HT-29和MKN-45）的体外生物学活性）。大多数化合物在酶和细胞分析中均显示中等至出色的活性。 与福瑞替尼相比，最有前途的类似物58（c-Met IC 50 = 1.42 nM）对H460和MKN-45细胞株分别显示出2.1倍，8.6倍的增长。对结构-活性关系的分析表明，邻位取代的苯环以及N-未取代的咪唑啉酮连接基有利于抗肿瘤活性。
• [EN] SUBSTITUTED AMIDE COMPOUNDS<br/>[FR] COMPOSÉS D'AMIDE SUBSTITUÉ
  申请人：PFIZER

  公开号：WO2016055901A1

  公开（公告）日：2016-04-14

  The present invention is directed at substituted amide compounds of formula (I), pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.(Formula I)

  本发明涉及式(I)的取代酰胺化合物，含有这种化合物的药物组合物，以及利用这种化合物降低血浆脂质水平，如LDL-胆固醇和甘油三酯，并据此治疗由高水平的LDL-胆固醇和甘油三酯加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物中，包括人类。(式I)
• [EN] ANTHELMINTIC COMPOUNDS, COMPOSITIONS AND METHOD OF USING THEREOF<br/>[FR] COMPOSÉS ANTHELMINTIQUES, COMPOSITIONS ET LEUR PROCÉDÉ D'UTILISATION
  申请人：MERIAL INC

  公开号：WO2016118638A1

  公开（公告）日：2016-07-28

  The present invention relates to novel anthelmintic compounds of formula (IA) below: wherein, Y is selected from the group consisting of -H, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkyl, haloalkyl, and alkoxyalkyl; and Z is selected from the group consisting of aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkyl, haloalkyl, and alkoxyalkyl. Variables Ring A, Ring B, Ring C, X1, X6, and X8 are as defined herein. The invention also relates to parasiticidal compositions comprising the compounds, and methods and uses of the compounds for treating and preventing parasitic infections and infestations in animals.

  本发明涉及式(IA)的新型驱虫化合物：其中，Y选自-H、芳基、环烷基、环烯基、杂芳基、杂环基、烷基、卤代烷基和烷氧基烷基；Z选自芳基、环烷基、环烯基、杂芳基、杂环基、烷基、卤代烷基和烷氧基烷基。变量环A、环B、环C、X1、X6和X8如本文所定义。本发明还涉及包含这些化合物的杀虫组合物，以及使用这些化合物治疗和预防动物中的寄生虫感染和侵扰的方法和用途。
• [EN] NOVEL QUINAZOLINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF<br/>[FR] NOUVEAUX DERIVES DE QUINAZOLINE ET LEUR UTILISATION THERAPEUTIQUE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004087680A1

  公开（公告）日：2004-10-14

  The present invention relates to novel compounds of Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新型化合物，其化学式为（I），该化合物作为MCH受体拮抗剂。这些组合物在药物组合物中具有用途，包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食障碍，包括暴食症、厌食症、精神障碍，包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍，包括帕金森病、癫痫和成瘾症。